LLY

966.35

+1.98%↑

JNJ

221.39

+0.12%↑

ABBV

202.82

+0.84%↑

UNH

384.32

+1.29%↑

AZN

181.82

-0.27%↓

LLY

966.35

+1.98%↑

JNJ

221.39

+0.12%↑

ABBV

202.82

+0.84%↑

UNH

384.32

+1.29%↑

AZN

181.82

-0.27%↓

LLY

966.35

+1.98%↑

JNJ

221.39

+0.12%↑

ABBV

202.82

+0.84%↑

UNH

384.32

+1.29%↑

AZN

181.82

-0.27%↓

LLY

966.35

+1.98%↑

JNJ

221.39

+0.12%↑

ABBV

202.82

+0.84%↑

UNH

384.32

+1.29%↑

AZN

181.82

-0.27%↓

LLY

966.35

+1.98%↑

JNJ

221.39

+0.12%↑

ABBV

202.82

+0.84%↑

UNH

384.32

+1.29%↑

AZN

181.82

-0.27%↓

Home・Akcijų sąrašas・Cytokinetics Inc

Cytokinetics Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

74.53 -2.89

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

74.04

Max

78.45

Pagrindiniai rodikliai
By Trading Economics
Pajamos	123M -183M
Pardavimai	16M 18M
Pelno marža	-1,030.87
Darbuotojai	673
EBITDA	97M -180M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+29.87% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-08-06

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	-140M 8.2B
Ankstesnė atidarymo kaina	77.42
Ankstesnė uždarymo kaina	74.53

Naujienos nuotaikos

By Acuity

40%

60%

134 / 346 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Very Strong Bearish Evidence

32.3 / 40.43 Palaikymas ir pasipriešinimas

Cytokinetics Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-05-11 22:15; UTC

Įsigijimai, susijungimai, perėmimai

BMO Financial Group to Sell Transportation-, Vendor-Finance Businesses to Stonepeak

2026-05-11 23:46; UTC

Rinkos pokalbiai

Yen Consolidates as Traders Await Bessent's Meetings -- Market Talk

2026-05-11 23:44; UTC

Rinkos pokalbiai

Nikkei May Rise on AI Enthusiasm -- Market Talk

2026-05-11 23:33; UTC

Rinkos pokalbiai

Gold Rises on Possible Position Adjustments -- Market Talk

2026-05-11 22:37; UTC

Rinkos pokalbiai

CSL's Profit, Revenue Downgrade 'Not a Complete Surprise' -- Market Talk

2026-05-11 22:32; UTC

Uždarbis

Verde Clean Fuels 1Q Loss/Shr 5c >VGAS

2026-05-11 22:02; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Stellar Auto Sales Increase in Canada Could Be Tied to Return of EV Incentives -- Market Talk

2026-05-11 21:49; UTC

Uždarbis

Rigetti Computing Revenue Triples. Why the Quantum Stock Is Falling. -- Barrons.com

2026-05-11 21:42; UTC

Rinkos pokalbiai

Declining Hours Worked Should Keep Bank of Canada Firmly on Hold -- Market Talk

2026-05-11 21:32; UTC

Įsigijimai, susijungimai, perėmimai

Bank of Montreal to Sell Transportation Finance and Vendor Finance Businesses to Stonepeak

2026-05-11 21:32; UTC

Įsigijimai, susijungimai, perėmimai

BMO: Supports Strategy to Elevate Returns and Accelerate Growth, Transaction Accretive to Cap Ratios and ROE >BMO.T

2026-05-11 21:32; UTC

Įsigijimai, susijungimai, perėmimai

BMO: Positions Businesses for Continued Growth in Efficient Cap Structure >BMO.T

2026-05-11 21:32; UTC

Įsigijimai, susijungimai, perėmimai

BMO: To Invest in 19.9% Equity Interest, Enabling Continued Participation in the Businesses' Long-Term Value Creation >BMO.T

2026-05-11 21:31; UTC

Įsigijimai, susijungimai, perėmimai

BMO: Announces Strategic Sale of Transportation and Vendor Finance Businesses

2026-05-11 21:23; UTC

Įsigijimai, susijungimai, perėmimai

CSG Systems Sale to NEC Gets CFIUS Clearance

2026-05-11 21:12; UTC

Uždarbis

Ovintiv: Full-Yr Production Volumes Expected to Avg 620 to 645 MBOE/d, Full-Yr Expected Cap Investment of $2.25B to $2.35B >OVV

2026-05-11 21:12; UTC

Uždarbis

Ovintiv 1Q Loss/Shr $2.35 >OVV

2026-05-11 20:50; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2026-05-11 20:44; UTC

Uždarbis

Steris: Board Approves New $1B Shr Repurchase Program >STE

2026-05-11 20:43; UTC

Uždarbis

Whirlpool Shares Are Still Falling. Last Week's Earnings Might Be Why. -- Barrons.com

2026-05-11 20:32; UTC

Uždarbis

CleanSpark 2Q Loss/Shr $1.52 >CLSK

2026-05-11 20:32; UTC

Uždarbis

CleanSpark 2Q Rev $136.4M >CLSK

2026-05-11 20:30; UTC

Uždarbis

Hims & Hers Stock Sinks. Why Earnings Offered Wall Street a Big Surprise. -- Barrons.com

2026-05-11 20:30; UTC

Uždarbis

Steris 4Q Cont Ops EPS $2.24 >STE

2026-05-11 20:30; UTC

Uždarbis

Steris 4Q Rev $1.6B >STE

2026-05-11 20:30; UTC

Uždarbis

Steris Sees FY Adj EPS $11.10-Adj EPS $11.30 >STE

2026-05-11 20:30; UTC

Uždarbis

Steris 4Q Adj EPS $2.83 >STE

2026-05-11 20:22; UTC

Karštos akcijos

Stocks to Watch: Moderna, Intel, Micron, Fox -- WSJ

2026-05-11 19:37; UTC

Uždarbis

More Bad News at KKR's Private Credit Fund -- Barrons.com

2026-05-11 19:32; UTC

Rinkos pokalbiai

Oil Gains As Trump Rejects Iran's Response to U.S. Plan -- Market Talk

Akcijų palyginimas

Kainos pokytis

Cytokinetics Inc Prognozė

Kainos tikslas

By TipRanks

29.87% į viršų

12 mėnesių prognozė

Vidutinis 99.88 USD 29.87%

Aukščiausias 140 USD

Žemiausias 67 USD

Remiantis 19 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Cytokinetics Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

19 ratings

Pirkti

Laikyti

Parduoti

Remiantis 19 analitikų, pateikusių Cytokinetics Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

32.3 / 40.43Palaikymas ir pasipriešinimas

Recent bearish events outweigh bullish events.

There is one bearish event.

Rinkos nuotaikos

By Acuity

134 / 346 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Cytokinetics Inc

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. It develops small molecule drug candidates primarily engineered to impact muscle function and contractility. The company's drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. It also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. The company has a strategic alliance with Ji Xing Pharmaceuticals Limited; and a collaboration and license agreement for the development and commercialization of aficamten in Japan for the treatment of patients with obstructive and non-obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.